masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Apoptosis Autocrine Signaling Biology of neoplasia Biomarkers Bladder Cancer Brain Breast Cancer Cardiovascular Disease CDKN2A mutation Cells Circulating miRNAs Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Efficacy EMT Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Head and Neck Cancer Heart HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Checkpoint Inhibitors Immune Response Immuno-Oncology Immunotherapy Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymphoma Melanoma Mesothelioma Microenvironment miRNA Molecular Characterization Mouse mRNA custom Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets Oral Cancer Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PIK3CA mutation Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma Sub-typing Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2021

2020

Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.

Moura, D. S., et al. Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study. J  Clin Oncol 38: 2020 (suppl; abstr 11546). DOI: 10.1200/JCO.2020.38.15_suppl.11546

Download jpg 6.0MB
View External Link

Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).

Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258). 

View External Link

Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial.

Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

2019

Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.

Battaglin, F., et al. Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2019, Chicago, IL

View External Link

Page last updated April 09, 2021